TY - JOUR T1 - Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19 JF - medRxiv DO - 10.1101/2021.06.10.21258714 SP - 2021.06.10.21258714 AU - Emily A. Blumberg AU - Pablo Tebas AU - Ian Frank AU - Amy Marshall AU - Anne Chew AU - Elizabeth A. Veloso AU - Alison Carulli AU - Walter Rogal AU - Avery L. Gaymon AU - Aliza H. Schmidt AU - Tiffany Barnette AU - Renee Jurek AU - Hooman Noorchashm AU - Wei-Ting Hwang AU - Julia Han Noll AU - Joseph A. Fraietta AU - Carl H. June AU - Elizabeth O. Hexner Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/15/2021.06.10.21258714.abstract N2 - Coronavirus Disease 2019 (COVID-19) remains a global health emergency with limited treatment options, lagging vaccine rates and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine storm. Cyclosporine A (CSA) is a calcineurin inhibitor that modulates cytokine production and may have direct antiviral properties against coronaviruses. To test whether a short course of treatment was safe in COVID-19 patients, we treated 10 hospitalized, oxygen requiring, non-critically ill patients with CSA at a starting dose of 9mg/kg/day. Five patients experienced adverse events, none were serious, and transaminitis was most common. No subject enrolled in this trial required intensive care unit (ICU)-level care and all patients were discharged alive from the hospital. Further, CSA treatment was associated with significant reductions in serum cytokines and chemokines important in COVID-19 hyper-inflammation, including CXCL10. In conclusion, short courses of CSA appear safe and feasible in COVID-19 patients requiring oxygen and therefore, may be a useful adjunct in resource-poor or resource-limited health care settings.Competing Interest StatementJoseph A. Fraietta and Carl H. June receive research funding supported in part by a grant from the Parker Institute for Cancer Immunotherapy.Clinical TrialClinicalTrials.gov: NCT04412785Funding StatementThis study was supported through internal funding from the Center for Cellular Immunotherapies at the University of Pennsylvania.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This investigator-initiated trial protocol was approved by the Institutional Review Board (IRB) at the University of Pennsylvania and was overseen by the Center for Cellular Immunotherapies (IND#149997, ClinicalTrials.gov identifier: NCT04412785). Informed consent was obtained from each patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny data that support the findings of this study are available from the corresponding author upon reasonable request. ER -